Patents by Inventor James Swarbrick
James Swarbrick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8968778Abstract: The present invention relates to pharmaceutical formulations for the controlled delivery of threo-3-(3,4-dihydroxyphenyl)serine (threo-DOPS) and derivatives of it. Such formulations can contain an extended or slow release component that maintains therapeutic concentration of threo-DOPS in the blood plasma over a prolonged time period. They can be further combined with an immediate release formulation to produce a product that, when administered to a patient in need thereof, results in substantially steady levels of active drug, eliminating the sharp peaks and troughs in blood plasma drug levels experienced with the existing threo-DOPS formulations.Type: GrantFiled: May 10, 2013Date of Patent: March 3, 2015Assignee: Lundbeck NA Ltd.Inventors: Stephen Peroutka, James Swarbrick
-
Publication number: 20130243875Abstract: The present invention relates to pharmaceutical formulations for the controlled delivery of threo-3-(3,4-dihydroxyphenyl)serine (threo-DOPS) and derivatives of it. Such formulations can contain an extended or slow release component that maintains therapeutic concentration of threo-DOPS in the blood plasma over a prolonged time period. They can be further combined with an immediate release formulation to produce a product that, when administered to a patient in need thereof, results in substantially steady levels of active drug, eliminating the sharp peaks and troughs in blood plasma drug levels experienced with the existing threo-DOPS formulations.Type: ApplicationFiled: May 10, 2013Publication date: September 19, 2013Applicant: CHELSEA THERAPEUTICS, INC.Inventors: Stephen Peroutka, James Swarbrick
-
Patent number: 8460705Abstract: The present invention relates to pharmaceutical formulations for the controlled delivery of threo-3-(3,4-dihydroxyphenyl)serine (threo-DOPS) and derivatives of it. Such formulations can contain an extended or slow release component that maintains therapeutic concentration of threo-DOPS in the blood plasma over a prolonged time period. They can be further combined with an immediate release formulation to produce a product that, when administered to a patient in need thereof, results in substantially steady levels of active drug, eliminating the sharp peaks and troughs in blood plasma drug levels experienced with the existing threo-DOPS formulations.Type: GrantFiled: March 13, 2012Date of Patent: June 11, 2013Assignee: Chelsea Therapeutics, Inc.Inventors: Stephen Peroutka, James Swarbrick
-
Publication number: 20120171297Abstract: The present invention relates to pharmaceutical formulations for the controlled delivery of threo-3-(3,4-dihydroxyphenyl)serine (threo-DOPS) and derivatives of it. Such formulations can contain an extended or slow release component that maintains therapeutic concentration of threo-DOPS in the blood plasma over a prolonged time period. They can be further combined with an immediate release formulation to produce a product that, when administered to a patient in need thereof, results in substantially steady levels of active drug, eliminating the sharp peaks and troughs in blood plasma drug levels experienced with the existing threo-DOPS formulations.Type: ApplicationFiled: March 13, 2012Publication date: July 5, 2012Inventors: Stephen Peroutka, James Swarbrick
-
Patent number: 8158149Abstract: The present invention relates to pharmaceutical formulations for the controlled delivery of threo-3-(3,4-dihydroxyphenyl)serine (threo-DOPS) and derivatives of it. Such formulations can contain an extended or slow release component that maintains therapeutic concentration of threo-DOPS in the blood plasma over a prolonged time period. They can be further combined with an immediate release formulation to produce a product that, when administered to a patient in need thereof, results in substantially steady levels of active drug, eliminating the sharp peaks and troughs in blood plasma drug levels experienced with the existing threo-DOPS formulations.Type: GrantFiled: January 29, 2007Date of Patent: April 17, 2012Assignee: Chelsea Therapeutics, Inc.Inventors: Stephen Peroutka, James Swarbrick
-
Publication number: 20070122479Abstract: The present invention relates to pharmaceutical formulations for the controlled delivery of threo-3-(3,4-dihydroxyphenyl)serine (threo-DOPS) and derivatives of it. Such formulations can contain an extended or slow release component that maintains therapeutic concentration of threo-DOPS in the blood plasma over a prolonged time period. They can be further combined with an immediate release formulation to produce a product that, when administered to a patient in need thereof, results in substantially steady levels of active drug, eliminating the sharp peaks and troughs in blood plasma drug levels experienced with the existing threo-DOPS formulations.Type: ApplicationFiled: January 29, 2007Publication date: May 31, 2007Inventors: Stephen Peroutka, James Swarbrick
-
Publication number: 20070004688Abstract: Disclosed are pharmaceutical compositions comprising an active vitamin D compound in emulsion pre-concentrate formulations, as well as emulsions and sub-micron droplet emulsions produced therefrom. The compositions comprise a lipophilic phase component, one or more surfactants, and an active vitamin D compound. The compositions may optionally further comprise a hydrophilic phase component.Type: ApplicationFiled: September 6, 2006Publication date: January 4, 2007Inventors: Barbara Laidlaw, James Swarbrick
-
Publication number: 20060105036Abstract: The present invention relates to pharmaceutical formulations for the controlled delivery of threo-3-(3,4-dihydroxyphenyl)serine (threo-DOPS) and derivatives of it. Such formulations can contain an extended or slow release component that maintains therapeutic concentration of threo-DOPS in the blood plasma over a prolonged time period. They can be further combined with an immediate release formulation to produce a product that, when administered to a patient in need thereof, results in substantially steady levels of active drug, eliminating the sharp peaks and troughs in blood plasma drug levels experienced with the existing threo-DOPS formulations.Type: ApplicationFiled: May 12, 2004Publication date: May 18, 2006Inventors: Stephen Peroutka, James Swarbrick
-
Publication number: 20050026877Abstract: Disclosed are pharmaceutical compositions comprising an active vitamin D compound in emulsion pre-concentrate formulations, as well as emulsions and sub-micron droplet emulsions produced therefrom. The compositions comprise a lipophilic phase component, one or more surfactants, and an active vitamin D compound. The compositions may optionally further comprise a hydrophilic phase component.Type: ApplicationFiled: May 10, 2004Publication date: February 3, 2005Inventors: Andrew Chen, Jun Fan, Xi-Yun Yu, Martha Whitehouse, Barbara Laidlaw, James Swarbrick
-
Publication number: 20050020546Abstract: Disclosed are pharmaceutical compositions comprising an active vitamin D compound in emulsion pre-concentrate formulations, as well as emulsions and sub-micron droplet emulsions produced therefrom. The compositions comprise a lipophilic phase component, one or more surfactants, and an active vitamin D compound. The compositions may optionally further comprise a hydrophilic phase component.Type: ApplicationFiled: June 10, 2004Publication date: January 27, 2005Inventors: Barbara Laidlaw, James Swarbrick
-
Patent number: 5976570Abstract: A process for making pharmaceutical dosage units containing a therapeutic quantity of one or more low dosage medicinal agent comprising granulating said medicinal agent in an aqueous medium which contains a pharmaceutically acceptable surfactant agent and, optionally, further processing the product of said granulating into a tablet or capsule dosage unit.Type: GrantFiled: July 15, 1996Date of Patent: November 2, 1999Assignee: Applied Analytical Industries, Inc.Inventors: Frank C. Greaves, James Swarbrick, Martin W. Beasley, Andrew W. Suddith, Henry C. Caldwell
-
Patent number: 5928668Abstract: Disclosed is a method of dry blend compression of potent drugs with low solubility, such as steroidal medicaments using directly compressible agglomerated excipients that are not a conventional or spray dried polyalcohol or lactose. The agglomerated excipients include mannitol, maltodextrin or corn syrup solids, which hold the medicament(s) in the crevices of the agglomerates. Also disclosed are the critical ratios of the agglomerated excipients to steroidal agent, specifically estradiol, that is distributed uniformly throughout the dry blend and then compressed into tablets.Type: GrantFiled: August 1, 1996Date of Patent: July 27, 1999Assignee: Applied Analytical Industries, Inc.Inventors: Frank C. Greaves, James Swarbrick, Martin W. Beasley
-
Patent number: 5538737Abstract: The present invention provides pharmaceutical capsule compositions for the oral administration of an H.sub.2 -antagonist. The composition includes a capsule containing an emulsion having a water portion and an oil portion. A pharmaceutically acceptable salt of an H.sub.2 -antagonist is dissolved in the water portion. The composition delivers a therapeutically effective amount of the H.sub.2 -antagonist to a patient in need thereof. The present invention also provides methods of making the capsule composition.Type: GrantFiled: November 30, 1994Date of Patent: July 23, 1996Assignee: Applied Analytical Industries, Inc.Inventors: Thomas W. Leonard, David P. Hause, Frederick D. Sancilio, James Swarbrick, Edward S. Wilson
-
Patent number: 4731359Abstract: The time during which a drug is pharmacologically active is prolonged by coating the drug with at least one chemical derivative of the drug having minor relative pharmacological activity.Type: GrantFiled: February 6, 1984Date of Patent: March 15, 1988Assignee: University of Southern CaliforniaInventor: James Swarbrick
-
Patent number: 4461776Abstract: The time during which a drug is pharmacologically active is prolonged by coating the drug with at least one chemical derivative of the drug having minor relative pharmacological activity.Type: GrantFiled: January 28, 1982Date of Patent: July 24, 1984Assignee: University of Southern CaliforniaInventor: James Swarbrick